Pfizer is interested in supporting proposals that prioritize education on the cerebrovascular and neurologic impact of sickle cell disease.

Proposals that address impact on other organ systems, particularly renal, will also be considered. Priority will be given to proposals that contain education at a congress attended by sickle cell providers.

See complete details